Swiss biopharmaceutical company Telormedix has raised $6.6m in a series-B financing round extension from existing backers Aravis Venture and Proquest Investments.
Managing director Craig Ferguson discusses accelerated deployment activity during the pandemic and plans to scale up the PE allocation by 2025
Fund has a target of $600m, which it plans to reach by next year, according to Kommersant
Existing investors including Institut Català de Finances also take part in the financing
Biotech company initially raised €12m in December 2018